Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview
Author:
Affiliation:
1. Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL, USA and
2. Zydus Research Centre, Ahmedabad, Gujarat, India
Publisher
Informa UK Limited
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/00498254.2016.1247219
Reference53 articles.
1. Glucose transporters: Structure, function and consequences of deficiency
2. Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design
3. SGLT-2 Inhibitors: A New Mechanism for Glycemic Control
4. Rosiglitazone
5. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Methodology of clinical trials on sodium-glucose cotransporter 2 inhibitors registered on ClinicalTrials.gov: a cross-sectional study;BMC Medical Research Methodology;2024-07-30
2. A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study;Diabetes, Obesity and Metabolism;2024-03-08
3. A green reversed phase HPLC and HPTLC methods and their validation for simultaneous estimation of remogliflozin, vildgliptin and metformin in fixed dose combination formulation;Journal of Liquid Chromatography & Related Technologies;2023-12-03
4. Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial;Diabetes & Metabolism Journal;2023-11-30
5. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives;Journal of Medicinal Chemistry;2022-08-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3